Bellerophon Says Phase 3 REBUILD Clinical Trial Did Not Meet Its Primary Endpoint
Portfolio Pulse from Benzinga Newsdesk
Bellerophon's Phase 3 REBUILD clinical trial for INOpulse® did not meet its primary endpoint, with iNO45 performing worse than placebo. Secondary endpoints showed minimal difference, and no safety concerns were observed.
June 05, 2023 | 11:01 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Bellerophon's stock may be negatively impacted as the Phase 3 REBUILD clinical trial for INOpulse® failed to meet its primary endpoint.
The failure of the Phase 3 REBUILD clinical trial to meet its primary endpoint indicates that the INOpulse® product may not be as effective as previously thought. This could lead to a decline in investor confidence and a negative impact on Bellerophon's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100